Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Is It Pfizer Now That's Dodging Tax In The UK?
Forbes
Sunday, November 11, 2012 - 9:25am
tags:
Pfizer
Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting®
Yahoo/PR NewsWire
Sunday, November 11, 2012 - 9:24am
tags:
Abbott Laboratories, hepatitis C
3 Horrendous Health-Care Stocks This Week
Motley Fool
Sunday, November 11, 2012 - 9:21am
tags:
Vivus, Orexigen, OraSure
This Week in Biotech: Part 2
Motley Fool
Sunday, November 11, 2012 - 9:19am
tags:
Biocryst, Catalyst Pharmaceutical Partners, Pluristem Therapeutics, Vivus, Arena Pharmaceuticals, Eisai
This Week in Biotech: Part 1
Motley Fool
Sunday, November 11, 2012 - 9:17am
tags:
Novartis, Novo Nordisk, Corcept Therapeutics, Biomarin, Sequenom
Supreme Court (in Canada) paves way for generic Viagra, ends monopoly
Canada.com, Canada
Saturday, November 10, 2012 - 8:40am
tags:
Viagra, Pfizer
Teva Pharmaceutical - A Fundamentals-Driven Dividend Growth Stock Value Idea For November 5
Seeking Alpha
Saturday, November 10, 2012 - 8:37am
tags:
Teva Pharmaceuticals
Will This Big Pharma Continue to Trade Up?
Motley Fool
Saturday, November 10, 2012 - 8:32am
tags:
Eli Lilly
Does VIVUS Need a Partner?
Motley Fool
Saturday, November 10, 2012 - 8:27am
tags:
Vivus, Qsymia, weight loss, obesity
Abraxane Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study
Yahoo/BusinessWire
Saturday, November 10, 2012 - 8:25am
tags:
Abraxane, pancreatic cancer
Pluristem Wants Bloomberg Retraction, Array Sets Secondary: Healthcare Business Wrap
Wall St Cheat Street
Saturday, November 10, 2012 - 8:23am
tags:
Pluristem Therapeutics, Array Biopharma
5 Healthcare Companies With Insider Buying During November 2012 - Part III
Seeking Alpha
Saturday, November 10, 2012 - 8:21am
tags:
Corcept Therapeutics, ChemoCentryx, GSK, Valeant Pharmaceuticals, HealthSouth
3 Humongous Health-Care Stocks This Week
Motley Fool
Saturday, November 10, 2012 - 8:19am
tags:
Biomarin, InterMune, Idenix
Industry Voices: The Impact of the 2012 Election on Pharma Is All about Product Value
Fierce Pharma
Friday, November 9, 2012 - 11:57am
tags:
Affordable Care Act
The January Effect And 3 Biopharma Stocks
Seeking Alpha
Friday, November 9, 2012 - 11:38am
tags:
Arena Pharmaceuticals, Dendreon, Horizon Pharma
Teva's seasonal allergy drug found effective in children
Reuters
Friday, November 9, 2012 - 11:37am
tags:
Teva, allergic rhinitis, Qnasi
Aastrom Biosciences' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Friday, November 9, 2012 - 11:35am
tags:
Aastrom Biosciences, earning
CVS shucking more drugs from its coverage list
Fierce Pharma
Friday, November 9, 2012 - 11:26am
tags:
CVS, pharmacy benefits, Allergan, Lumigan, Androgel, Abbott Labs, Pfizer, Genotropin, Bristol-Myers Squibb, AstraZeneca, Onglyza
2 Speculative Biotech Plays That Have Potential
Seeking Alpha
Friday, November 9, 2012 - 11:22am
tags:
Jazz Pharmaceuticals, Zogenix
Esbriet Sales Demonstrating Growth; Expansion into New Markets Continues
Yahoo/Reuters
Friday, November 9, 2012 - 11:21am
tags:
Esbriet, InterMune

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.